Coeptis Therapeutics Holdings, INC 8-K filings

Z Squared Inc. has signed a definitive agreement to acquire 100% of Paradox Data, LLC, securing a data center site in Arkansas with a pathway to 150 MW of AI-ready capacity.

Z Squared Inc. has terminated its At Market Offering and Committed Equity Forward Purchase agreements, citing sufficient operating runway and a desire to eliminate potential dilution.

Z Squared Inc. has amended its Letter of Intent for the acquisition of Skycore Digital LLC, extending the drop-dead date and eliminating the break-up fee.

Z Squared Inc. has entered into a Sales Agreement to offer and sell up to $300 million of its common stock through Roth Capital Partners, LLC.

Z Squared Inc. announced the appointment of Jeffery Harris as Chief Technology Officer, effective June 24, 2026, coinciding with the company's binding letter of intent to acquire a majority stake in Paradox Data LLC.

Z Squared Inc. announced the completion of a $15.3 million equity financing and its inclusion in the Russell 3000 and Russell 2000 Indexes, bolstering its AI infrastructure strategy.

Z Squared Inc. announced a $50 million committed equity forward purchase agreement with LucentHash / Data Part Capital to fund its AI infrastructure buildout.

Z Squared Inc. announces the resignation of Co-CEO Michelle Burke, leaving David Halabu as the sole Chief Executive Officer.

Z Squared Inc. completes merger, appoints new leadership, and signs a binding LOI to acquire Skycore Digital for AI expansion.

Z Squared Inc. completes its reverse merger with Coeptis Therapeutics Holdings, Inc., rebranding and shifting its core business to large-scale Dogecoin and Litecoin cryptocurrency mining operations.

Z Squared, Inc. provides supplemental information on its business combination with Coeptis Therapeutics Holdings, Inc. and a pro rata dividend distribution.

Z Squared has finalized its business combination with Coeptis Therapeutics and will begin trading on the Nasdaq Global Market under the ticker ZSQR on April 27, 2026.

Coeptis Therapeutics Holdings, Inc. announced it has regained compliance with Nasdaq listing rules and implemented a one-time option repricing and exchange program for officers and directors.

Coeptis Therapeutics Holdings, Inc. stockholders overwhelmingly approved all key proposals, including the merger with Z Squared, a biopharmaceutical spin-out, and a corporate name change.

Coeptis Therapeutics Holdings, Inc. received a Nasdaq delisting notice for failing to hold its annual shareholder meeting, but plans to regain compliance by January 30, 2026.

Coeptis Therapeutics is set to merge with Z Squared, a Dogecoin mining company, while spinning out its biopharmaceutical operations.

Colleen Delaney resigns as Chief Scientific and Medical Officer of Coeptis Therapeutics Holdings, effective March 24, 2025, to pursue another business opportunity.

Coeptis Therapeutics Holdings, Inc. has entered into a convertible promissory note agreement for $1.1 million and completed a $10 million Series A preferred stock offering.

Coeptis Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

Coeptis Therapeutics will implement a 1-for-20 reverse stock split effective December 30, 2024, to meet Nasdaq's minimum bid price requirement.

Coeptis Therapeutics held its annual meeting on December 18, 2024, where stockholders voted on several key proposals, including the election of directors, ratification of auditors, and approval of a reverse stock split.

Coeptis Therapeutics is expanding into the technology sector by acquiring assets from a risk mitigation software company, marking a significant diversification of its business.

Coeptis Therapeutics has announced a binding letter of intent to acquire NexGenAI Affiliates Network, an AI-powered marketing and robotic process automation platform.

Coeptis Therapeutics Holdings, Inc. has entered into a Standby Equity Purchase Agreement with YA II PN, LTD for up to $20 million in funding.

Coeptis Therapeutics Holdings has changed its independent registered public accounting firm from Turner, Stone & Company to Astra Audit & Advisory, effective immediately on September 24, 2024.

Coeptis Therapeutics has been granted an extension until January 15, 2025, by the Nasdaq Hearings Panel to regain compliance with the minimum bid price requirement for continued listing.

Coeptis Therapeutics has determined that previously issued financial statements for multiple periods should no longer be relied upon due to accounting errors related to note agreements.

Coeptis Therapeutics Holdings, Inc. received a delisting notice from Nasdaq after failing to maintain a minimum share price of $1.00, and is planning to appeal the decision.

Coeptis Therapeutics has successfully raised $4.3 million through a Series A preferred stock offering, led by a board member, to bolster its cell therapy platform development.

Coeptis Therapeutics Holdings, Inc. announced it will restate its financial statements from 2022 and 2023 due to accounting errors related to a merger and a research agreement.